2023
1538. Is there value in performing yearly screening for latent tuberculosis infection by interferon-gamma release assay among patients living with HIV in non-endemic settings?
Palacios C, Achhra A, Barakat L, Virata M, Hao R, Baxter J, Malinis M. 1538. Is there value in performing yearly screening for latent tuberculosis infection by interferon-gamma release assay among patients living with HIV in non-endemic settings? Open Forum Infectious Diseases 2023, 10: ofad500.1373. PMCID: PMC10678242, DOI: 10.1093/ofid/ofad500.1373.Peer-Reviewed Original ResearchInterferon-gamma release assaysLatent tuberculosis infectionNew latent tuberculosis infectionsTuberculin skin testingNon-endemic settingRisk factorsCD4 countTuberculosis infectionCurrent guidelinesGroup APositive interferon-gamma release assaysHigher HIV viral loadUrban academic medical centerChest imaging resultsLow CD4 countTB exposure riskTB risk factorsCells/mm3HIV viral loadRetrospective chart reviewFeatures of patientsRisk of reactivationInterferon-gamma releaseCommon risk factorsAcademic medical center
2020
543. SARS-CoV-2 Viral Dynamics For Symptomatic People Living with HIV Requiring Hospitalization For COVID-19
Virata M, Villanueva M, Shenoi S, Ladines-Lim J, Aoun-Barakat L. 543. SARS-CoV-2 Viral Dynamics For Symptomatic People Living with HIV Requiring Hospitalization For COVID-19. Open Forum Infectious Diseases 2020, 7: s338-s338. PMCID: PMC7777445, DOI: 10.1093/ofid/ofaa439.737.Peer-Reviewed Original ResearchSARS-CoV-2 viral loadViral loadRespiratory samplesViral dynamicsUndetectable HIV viral loadSARS-CoV-2 infectionSevere acute respiratory syndrome 2SARS-CoV-2 viral dynamicsMedian CD4 countRetrospective cohort studyCells/mm3HIV viral loadRNA viral loadMain outcome measuresUrban academic centerCT of patientsPresentation of illnessYears of ageCOVID-19SARS-CoV-2COVID-19 diseaseCycle threshold valuesHospital mortalityAdvanced diseaseCD4 count
2017
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva M, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017, 6: 620. DOI: 10.12688/f1000research.11397.1.Peer-Reviewed Original ResearchHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection